iNetworks Management Announces Investment in INDIGO Biosciences
iNetworks announced today an initial milestone investment in INDIGO Biosciences, Inc., State College, PA. INDIGO Biosciences, a leader in cell-based nuclear receptor assay products and services, serves the worldwide pharmaceutical industry from its State College facility. iNetworks was instrumental in the hiring of the new CEO of INDIGO, Mr. Fred Marroni and will enable further development of international markets for INDIGO’s base products and services. This enhanced international strategy will also include selective roll up product acquisitions as well as distribution opportunities in Europe and Canada. iNetworks will have significant Board representation.
Founded in 1999, iNetworks helps companies and entrepreneurs accelerate their solutions by providing capital and intellectual resources to solve critical problems. iNetworks focuses primarily on healthcare and life sciencesA cluster of scientific disciplines concerned with human life and health. Included are many branches of biology (e.g., molecular biology, cell biology) and chemistry (e.g., biochemistry), as well as some areas of genetics, physics and materials science, among others. businesses that develop breakthrough technologies to improve clinical outcomes for patients and save time, money, and resources for healthcare providers. Learn more at www.inetworksllc.com.
About INDIGO Biosciences
INDIGO Biosciences, Inc. was founded in 2005 in State College, PA by Dr. Jack Vanden Heuvel and Dr. Blake Peterson. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets. The Company’s two founders leveraged their collective expertise in nuclear receptor biology, toxicology, medicinal chemistry and molecular biology to establish the core platform technology of The Company.